Respiratory System Panel (RSP)

Acute Respiratory Infections (ARIs) are serious infections that prevent normal breathing functions, usually beginning as a viral infection in the nose, trachea (windpipe), or lungs. Furthermore, ARIs prevent the body from getting oxygen and can result in death. Accurate diagnosis and timing are critical to the survival of the patient. Results from a rapid test can lead to a false sense of security for both the patient and the clinician, resulting in the delay of an accurate diagnosis and the progression of the disease.

In the United States, 2,800,000 people have serious antibiotic-resistant infections, and more than 35,000 people die from these infections each year.

Absolute DXS utilizes comprehensive molecular diagnostics designed to rapidly differentiate and identify various pathogens found in respiratory illnesses and diseases; greatly reducing the hazards associated with susceptibility tests and their associated application of broad-spectrum antibiotics that can produce harmful antibiotic resistance.

PREVENTION

Absolute DXS offers comprehensive molecular diagnostic testing to aide clinicians in providing accurate and appropriate time-sensitive treatments for their patients; thereby contributing to the following:

DETECTION

Absolute DXS leverages innovative technologies and complex techniques to assist clinicians in disease detection and help physicians to precisely diagnose patients, early on.

SENSITIVITY

Absolute DXS’ real-time PCR, Toxicology and Blood Specimen testing allows for highly accurate results for highly targeted treatment with sensitivity at the patient, not the protocol level.